Chemicals
Build Your Comparison
Side-by-side financial analysisStock Comparison
ORGN vs GEVO vs LOOP vs CLNE vs HYLN
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
Chemicals - Specialty
Oil & Gas Refining & Marketing
Auto - Parts
ORGN vs GEVO vs LOOP vs CLNE vs HYLN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Chemicals | Chemicals - Specialty | Chemicals - Specialty | Oil & Gas Refining & Marketing | Auto - Parts |
| Market Cap | $6M | $375M | $40M | $410M | $1.44B |
| Revenue (TTM) | $14M | $174M | $514K | $439M | $6M |
| Net Income (TTM) | $-241M | $-34M | $-12M | $-99M | $-52M |
| Gross Margin | -4.4% | 47.3% | -11.9% | 16.6% | -112.7% |
| Operating Margin | -459.3% | -4.6% | -19.7% | -8.2% | -10.4% |
| Total Debt | $28M | $168M | $3M | $99M | $4M |
| Cash & Equiv. | $33M | $1M | $2M | $158M | $23M |
ORGN vs GEVO vs LOOP vs CLNE vs HYLN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | Jun 26 | Return |
|---|---|---|---|
| Origin Materials, I… (ORGN) | 100 | 0.4 | -99.6% |
| Gevo, Inc. (GEVO) | 100 | 154.0 | +54.0% |
| Loop Industries, In… (LOOP) | 100 | 6.1 | -93.9% |
| Clean Energy Fuels … (CLNE) | 100 | 75.0 | -25.0% |
| Hyliion Holdings Co… (HYLN) | 100 | 16.3 | -83.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ORGN vs GEVO vs LOOP vs CLNE vs HYLN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ORGN is the clearest fit if your priority is income & stability.
- Dividend streak 1 yrs, beta 1.54
GEVO carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 8.5%, EPS growth 58.8%, 3Y rev CAGR 415.1%
- 8.5% revenue growth vs LOOP's -95.3%
- -19.4% margin vs LOOP's -23.9%
- -4.9% ROA vs LOOP's -100.3%
Among these 5 stocks, LOOP doesn't own a clear edge in any measured category.
CLNE is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.48, Low D/E 17.5%, current ratio 2.32x
- Beta 0.48, current ratio 2.32x
- Beta 0.48 vs HYLN's 2.57
HYLN ranks third and is worth considering specifically for long-term compounding.
- -16.5% 10Y total return vs CLNE's -45.1%
- +462.5% vs ORGN's -91.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.5% revenue growth vs LOOP's -95.3% | |
| Quality / Margins | -19.4% margin vs LOOP's -23.9% | |
| Stability / Safety | Beta 0.48 vs HYLN's 2.57 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +462.5% vs ORGN's -91.8% | |
| Efficiency (ROA) | -4.9% ROA vs LOOP's -100.3% |
ORGN vs GEVO vs LOOP vs CLNE vs HYLN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ORGN vs GEVO vs LOOP vs CLNE vs HYLN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GEVO leads in 2 of 6 categories
ORGN leads 2 • HYLN leads 1 • LOOP leads 0 • CLNE leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
GEVO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CLNE is the larger business by revenue, generating $439M annually — 854.3x LOOP's $514,000. Profitability is closely matched — net margins range from -19.4% (GEVO) to -23.9% (LOOP). On growth, HYLN holds the edge at +4.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $14M | $174M | $514,000 | $439M | $6M |
| EBITDAEarnings before interest/tax | -$55M | $21M | -$10M | $11M | -$53M |
| Net IncomeAfter-tax profit | -$241M | -$34M | -$12M | -$99M | -$52M |
| Free Cash FlowCash after capex | -$59M | -$44M | -$10M | $19M | -$64M |
| Gross MarginGross profit ÷ Revenue | -4.4% | +47.3% | -11.9% | +16.6% | -112.7% |
| Operating MarginEBIT ÷ Revenue | -4.6% | -4.6% | -19.7% | -8.2% | -10.4% |
| Net MarginNet income ÷ Revenue | -17.2% | -19.4% | -23.9% | -22.7% | -8.9% |
| FCF MarginFCF ÷ Revenue | -4.3% | -25.0% | -19.9% | +4.3% | -10.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -91.2% | +47.5% | -98.4% | +12.1% | +4.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +39.3% | +2.1% | -138.7% | +90.6% | +30.0% |
Valuation Metrics
ORGN leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, CLNE's 74.1x EV/EBITDA is more attractive than GEVO's 83.8x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $6M | $375M | $40M | $410M | $1.4B |
| Enterprise ValueMkt cap + debt − cash | $781,018 | $541M | $41M | $351M | $1.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.02x | -11.00x | -3.19x | -1.84x | -24.55x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 83.82x | — | 74.09x | — |
| Price / SalesMarket cap ÷ Revenue | 0.32x | 2.33x | 78.12x | 0.96x | 415.67x |
| Price / BookPrice ÷ Book value/share | 0.05x | 0.76x | — | 0.73x | 7.40x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 6.84x | — |
Profitability & Efficiency
GEVO leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
GEVO delivers a -7.2% return on equity — every $100 of shareholder capital generates $-7 in annual profit, vs $-121 for ORGN. HYLN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to GEVO's 0.36x. On the Piotroski fundamental quality scale (0–9), CLNE scores 5/9 vs LOOP's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -120.7% | -7.2% | — | -17.2% | -26.0% |
| ROA (TTM)Return on assets | -99.5% | -4.9% | -100.3% | -9.2% | -24.6% |
| ROICReturn on invested capital | -24.4% | -2.8% | — | -9.4% | -23.5% |
| ROCEReturn on capital employed | -25.7% | -3.1% | -99.2% | -9.4% | -29.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 1 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.27x | 0.36x | — | 0.18x | 0.02x |
| Net DebtTotal debt minus cash | -$5M | $166M | $679,000 | -$59M | -$19M |
| Cash & Equiv.Liquid assets | $33M | $1M | $2M | $158M | $23M |
| Total DebtShort + long-term debt | $28M | $168M | $3M | $99M | $4M |
| Interest CoverageEBIT ÷ Interest expense | -2627.81x | -0.66x | -6.22x | -0.71x | — |
Total Returns (Dividends Reinvested)
HYLN leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HYLN five years ago would be worth $6,841 today (with dividends reinvested), compared to $37 for ORGN. Over the past 12 months, HYLN leads with a +462.5% total return vs ORGN's -91.8%. The 3-year compound annual growth rate (CAGR) favors HYLN at 64.8% vs ORGN's -79.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -84.6% | -25.2% | -18.2% | -13.9% | +345.1% |
| 1-Year ReturnPast 12 months | -91.8% | +11.6% | -50.3% | -5.6% | +462.5% |
| 3-Year ReturnCumulative with dividends | -99.1% | +12.4% | -74.2% | -57.0% | +347.5% |
| 5-Year ReturnCumulative with dividends | -99.6% | -80.2% | -93.6% | -84.2% | -31.6% |
| 10-Year ReturnCumulative with dividends | -99.6% | -99.3% | -94.6% | -45.1% | -16.5% |
| CAGR (3Y)Annualised 3-year return | -79.4% | +4.0% | -36.3% | -24.5% | +64.8% |
Risk & Volatility
Evenly matched — CLNE and HYLN each lead in 1 of 2 comparable metrics.
Risk & Volatility
CLNE is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than HYLN's 2.57 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HYLN currently trades 95.4% from its 52-week high vs ORGN's 3.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.54x | 1.52x | 0.74x | 0.48x | 2.57x |
| 52-Week HighHighest price in past year | $28.49 | $2.97 | $2.11 | $3.11 | $8.49 |
| 52-Week LowLowest price in past year | $0.20 | $1.12 | $0.73 | $1.75 | $1.30 |
| % of 52W HighCurrent price vs 52-week peak | +3.8% | +51.9% | +39.3% | +59.8% | +95.4% |
| RSI (14)Momentum oscillator 0–100 | 33.6 | 36.4 | 31.5 | 36.0 | 67.4 |
| Avg Volume (50D)Average daily shares traded | 563K | 3.4M | 57K | 1.2M | 3.6M |
Analyst Outlook
ORGN leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ORGN as "Buy", GEVO as "Buy", CLNE as "Buy", HYLN as "Hold". Consensus price targets imply 8156.9% upside for ORGN (target: $90) vs 11.1% for HYLN (target: $9).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | — | Buy | Hold |
| Price TargetConsensus 12-month target | $90.00 | $2.75 | — | $3.50 | $9.00 |
| # AnalystsCovering analysts | 6 | 14 | — | 22 | 6 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +1.9% | 0.0% |
GEVO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ORGN leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
ORGN vs GEVO vs LOOP vs CLNE vs HYLN: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is ORGN or GEVO or LOOP or CLNE or HYLN a better buy right now?
For growth investors, Gevo, Inc.
(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -95. 3% for Loop Industries, Inc. (LOOP). Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ORGN or GEVO or LOOP or CLNE or HYLN?
Over the past 5 years, Hyliion Holdings Corp.
(HYLN) delivered a total return of -31. 6%, compared to -99. 6% for Origin Materials, Inc. (ORGN). Over 10 years, the gap is even starker: HYLN returned -16. 5% versus ORGN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ORGN or GEVO or LOOP or CLNE or HYLN?
By beta (market sensitivity over 5 years), Clean Energy Fuels Corp.
(CLNE) is the lower-risk stock at 0. 48β versus Hyliion Holdings Corp. 's 2. 57β — meaning HYLN is approximately 436% more volatile than CLNE relative to the S&P 500. On balance sheet safety, Hyliion Holdings Corp. (HYLN) carries a lower debt/equity ratio of 2% versus 36% for Gevo, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ORGN or GEVO or LOOP or CLNE or HYLN?
By revenue growth (latest reported year), Gevo, Inc.
(GEVO) is pulling ahead at 849. 3% versus -95. 3% for Loop Industries, Inc. (LOOP). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to -188. 2% for Origin Materials, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ORGN or GEVO or LOOP or CLNE or HYLN?
Gevo, Inc.
(GEVO) is the more profitable company, earning -21. 1% net margin versus -23. 9% for Loop Industries, Inc. — meaning it keeps -21. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEVO leads at -11. 7% versus -1970. 4% for LOOP. At the gross margin level — before operating expenses — GEVO leads at 30. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ORGN or GEVO or LOOP or CLNE or HYLN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ORGN or GEVO or LOOP or CLNE or HYLN better for a retirement portfolio?
For long-horizon retirement investors, Clean Energy Fuels Corp.
(CLNE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). Hyliion Holdings Corp. (HYLN) carries a higher beta of 2. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLNE: -45. 1%, HYLN: -16. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ORGN and GEVO and LOOP and CLNE and HYLN?
These companies operate in different sectors (ORGN (Basic Materials) and GEVO (Basic Materials) and LOOP (Basic Materials) and CLNE (Energy) and HYLN (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ORGN is a small-cap quality compounder stock; GEVO is a small-cap high-growth stock; LOOP is a small-cap quality compounder stock; CLNE is a small-cap quality compounder stock; HYLN is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.